Use of hyposmia and other non-motor symptoms to distinguish between drug-induced Parkinsonism and Parkinson's disease

Journal of Parkinson's Disease

Volumn 4, Issue 2, 2014, Pages 169-173

  Morley, James F ^a   Duda, John E ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Autonomic nervous system diseases; cognitive disorders; olfaction disorders; Parkinson disease; Parkinsonian syndrome; secondary

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; DOPAMINE RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT;

AUTONOMIC DYSFUNCTION; CLINICAL FEATURE; COGNITIVE DEFECT; DAYTIME SOMNOLENCE; DEMENTIA; DISEASE MARKER; DRUG INDUCED DISEASE; DRUG INDUCED PARKINSONISM; DYSAUTONOMIA; HUMAN; HYPOSMIA; OLFACTORY NERVE DISEASE; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; RATING SCALE; RESTLESS LEGS SYNDROME; REVIEW; RISK FACTOR; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP DISORDER; SYMPATHETIC INNERVATION; URINARY TRACT DISEASE; CHEMICALLY INDUCED; COMPLICATION; DIFFERENTIAL DIAGNOSIS; FEMALE; MALE; OLFACTION DISORDERS; PARKINSON DISEASE, SECONDARY;

ANTIPSYCHOTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; MALE; OLFACTION DISORDERS; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY;

EID: 84901835119     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-130299     Document Type: Review

References (38)

1. Wenning GK, Litvan I, & Tolosa E (2011) Milestones in atypical and secondary Parkinsonisms.Mov Disord, 26, 1083-1095.
2. Tarsy D (1983) Neuroleptic-induced extrapyramidal reactions: Classification, description, and diagnosis. Clin Neuropharmacol, 6(Suppl 1), S9-26.
3. Susatia F, & Fernandez HH (2009) Drug-induced parkinsonism. Curr Treat Options Neurol, 11, 162-169.
4. Hassin-Baer S, Sirota P, Korczyn AD, Treves TA, Epstein B, Shabtai H, Martin T, Litvinjuk Y, & Giladi N (2001) Clinical characteristics of neuroleptic-induced parkinsonism. J Neural Transm, 108, 1299-1308.
5. Sethi KD, & Zamrini EY (1990) Asymmetry in clinical features of drug-induced parkinsonism. J Neuropsychiatry Clin Neurosci, 2, 64-66.
6. Aronson TA (1985) Persistent drug-induced parkinsonism. Biol Psychiatry, 20, 795-798.
7. Wilson JA, Primrose WR, & Smith RG (1987) Prognosis of drug-induced Parkinson's disease. Lancet, 1, 443-444.
8. Melamed E, Achiron A, Shapira A, & Davidovicz S (1991) Persistent and progressive parkinsonism after discontinuation of chronic neuroleptic therapy: An additional tardive syndrome? Clin Neuropharmacol, 14, 273-278.
9. Kuzuhara S (1997) Drug-induced parkinsonism. Nihon Rinsho, 55, 112-117.
10. BarbosaMT, Caramelli P, Maia DP, Cunningham MC, Guerra HL, Lima-Costa MF, & Cardoso F (2006) Parkinsonism and Parkinson's disease in the elderly:Acommunity-based survey in Brazil (the Bambui study). Mov Disord, 21, 800-808.
11. Siderowf A,&LangAE(2012) Premotor Parkinson's disease: Concepts and definitions. Mov Disord, 27, 608-616.
12. Rajput AH, Rozdilsky B, Hornykiewicz O, Shannak K, Lee T, & Seeman P (1982) Reversible drug-induced parkinsonism. Clinicopathologic study of two cases. Arch Neurol, 39, 644-646.
13. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, & Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging, 24, 197-211.
14. Braak H, Bohl JR, Muller CM, Rub U, de Vos RA, & Del Tredici K (2006) Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov Disord, 21, 2042-2051.
15. Postuma RB, Gagnon JF, & Montplaisir J (2012) RBD as a biomarker for neurodegeneration: The past 10 years. Sleep Med, 14(8), 763-767. doi: 10.1016/j.sleep.2012.09.001
16. Savica R, Rocca WA, & Ahlskog JE (2010) When does Parkinson disease start? Arch Neurol, 67, 798-801.
17. Boeve BF, Silber MH, Ferman TJ, Lucas JA, & Parisi JE (2001) Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord, 16, 622-630.
18. Haehner A, Hummel T, Hummel C, Sommer U, Junghanns S, & Reichmann H (2007) Olfactory loss may be a first sign of idiopathic Parkinson's disease. Mov Disord, 22, 839-842.
19. Stephenson R, Siderowf A, & Stern MB (2009) Premotor Parkinson's disease: Clinical features and detection strategies. Mov Disord, 24(Suppl 2), S665-S670.
20. Kim JS, Youn J, Shin H, & Cho JW (2013) Nonmotor symptoms in drug-induced parkinsonism and drug-naive Parkinson disease. Can J Neurol Sci, 40, 36-41.
21. Chaudhuri KR, Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, Brown RG, KollerW, Barone P, MacPhee G, Kelly L, Rabey M, MacMahon D, Thomas S, Ondo W, Rye D, Forbes A, Tluk S, Dhawan V, Bowron A, Williams AJ, & Olanow CW (2006) International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study. Mov Disord, 21, 916-923.
22. Doty RL (2007) Olfaction in Parkinson's disease. Parkinsonism Relat Disord, 13(Suppl 3), S225-S228.
23. Ross GW, Petrovitch H, Abbott RD, Tanner CM, Popper J, Masaki K, Launer L,&WhiteLR(2008) Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol, 63, 167-173.
24. Morley JF, & Duda JE (2010) Olfaction as a biomarker in Parkinson's disease. Biomark Med, 4, 661-670.
25. Kruger S, Haehner A, Thiem C, & Hummel T (2008) Neuroleptic-induced parkinsonism is associated with olfactory dysfunction. J Neurol, 255, 1574-1579.
26. Lee PH, Yeo SH, Yong SW, & Kim YJ (2007) Odour identification test and its relation to cardiac 123I-metaiodobenzylguanidine in patients with drug induced parkinsonism. J Neurol Neurosurg Psychiatry, 78, 1250-1252.
27. Pfeiffer RF (2012) Autonomic dysfunction in Parkinson's disease. Expert Rev Neurother, 12, 697-706.
28. Orimo S, Suzuki M, Inaba A, & Mizusawa H (2012) 123I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism: A systematic review and meta-analysis. Parkinsonism Relat Disord, 18, 494-500.
29. Lee PH, Kim JS, Shin DH, Yoon SN, & Huh K (2006) Cardiac 123I-MIBG scintigraphy in patients with drug induced parkinsonism. J Neurol Neurosurg Psychiatry, 77, 372-374.
30. Aarsland D, Marsh L, & Schrag A (2009) Neuropsychiatric symptoms in Parkinson's disease. Mov Disord, 24, 2175-2186.
31. Kim JH, & Byun HJ (2009) Non-motor cognitive-perceptual dysfunction associated with drug-induced parkinsonism. Hum Psychopharmacol, 24, 129-133.
32. Kim YD, Kim JS, Chung SW, Song IU, Yang DW, Hong YJ, Kim YI, Ahn KJ, Kim HT, & Lee KS (2011) Cognitive dysfunction in drug induced parkinsonism (DIP). Arch Gerontol Geriatr, 53, e222-e226.
33. Shiba M, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, Schaid DJ, & RoccaWA (2000) Anxiety disorders and depressive disorders preceding Parkinson's disease: A case-control study. Mov Disord, 15, 669-677.
34. Cumming AG, Matthews NL, & Park S (2011) Olfactory identification and preference in bipolar disorder and schizophrenia. Eur Arch Psychiatry Clin Neurosci, 261, 251-259.
35. Ross GW, Abbott RD, Petrovitch H, Tanner CM, & White LR (2012) Pre-motor features of Parkinson's disease: The Honolulu-Asia Aging Study experience. Parkinsonism Relat Disord, 18(Suppl 1), S199-S202.
36. Stern MB,&SiderowfA(2010) Parkinson's at risk syndrome: Can Parkinson's disease be predicted? Mov Disord, 25 (Suppl 1), S89-S93.
37. Berendse HW, & Ponsen MM (2009) Diagnosing premotor Parkinson's disease using a two-step approach combining olfactory testing and DAT SPECT imaging. Parkinsonism Relat Disord, 15(Suppl 3), S26-S30.
38. BoviT, Antonini A, Ottaviani S, Antonioli A, CecchiniMP,Di Francesco V, Bassetto MA, Zamboni M, Fiaschi A, Moretto G, Sbarbati A, Osculati F, & Tinazzi M (2010) The status of olfactory function and the striatal dopaminergic system in drug-induced parkinsonism. J Neurol, 257, 1882-1889.